Bleeding complications and thromboembolic complications are frequent during extracorporeal
membrane oxygenation (ECMO). Retrospective data suggest that platelet inhibition using
prostaglandins, in this case PGE1, may reduce thromboembolic complications without increasing
the bleeding risk. This randomized, double-blind trial aims to investigate the effects of
PGE1 on bleeding risk, thromboembolic complications and the function of the ECMO.